Polyclonal antibodies against properly folded Dengue virus NS1 protein expressed in E. coli enable sensitive and early dengue diagnosis  by Allonso, Diego et al.
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The  non-structural  1  (NS1)  protein  plays  an  important  role  in dengue  diagnosis  because  it has  been
detected  as  a soluble  serum  antigen  in both  primary  and secondary  infections.  The  NS1  protein  was
expressed  in Escherichia  coli cells,  and  the  efﬁciency  of four  different  refolding  protocols  was  tested.  All
of  the  protocols  generated  dimeric  NS1  in a conformation  similar  to  that  of the  protein  expressed  by
eukaryotic  cells.  A polyclonal  antibody  produced  from  the  properly  folded  E. coli  recombinant  NS1  (rNS1)eywords:
engue virus
S1  protein
engue diagnosis
.  coli
protein  proved  to  be a useful  tool  for  the  diagnosis  of  Dengue  virus  because  it detected  100%  of  the
Dengue  virus  2 (DENV2)  in  infected  patients’  sera and  60%  of the  DENV  IgM-positive  sera  not  detected  by
commercial  NS1-based  diagnostic  kits.  These  data  suggest  a high-efﬁciency  method  for correctly  folding
rNS1  that  maintains  its  structural  and  immunogenic  properties.  In addition,  a  detection  method  using
the  polyclonal  antibody  against  correctly  folded  rNS1  seemed  to  be  more  sensitive  and  efﬁcient  for  NS1
detection  in  serum,  highlighting  its  usefulness  for developing  a high-sensitivity  diagnostic  kit.. Introduction
The NS1 is a glycoprotein of approximately 45 kDa that is con-
erved among ﬂaviviruses (Falgout et al., 1989; Rice et al., 1985;
hao et al., 1987). NS1 is naturally found as a plasma membrane-
ssociated, non-covalently linked homodimer (Winkler et al., 1988)
nd as a soluble multimer in the extracellular medium (Falconar
nd Young, 1991; Flamand et al., 1999). Data from the literature
how that the NS1 protein exhibits complement-ﬁxing activity
Smith and Wright, 1985), that may  be used as a protective antigen
Schlesinger et al., 1987) and it seems to be involved in viral RNA
eplication (Mackenzie et al., 1996), although its function in dengue
athogenesis remains poorly elucidated.The diagnosis of dengue diseases remains an open question
ecause current methods have limitations, such as high costs and
ow detection accuracy. Different laboratory diagnostic techniques
∗ Corresponding author at: Laboratorio de Genomica Estrutural, Instituto de
iofísica  Carlos Chagas Filho (UFRJ), Ediﬁcio do Centro de Ciencias da Saude, Bloco C
ala 36 sub-solo, Av. Carlos Chagas Filho, s/n - Cidade Universitaria, Ilha do Fundao,
EP: 21941-902, Rio de Janeiro, RJ, Brazil. Tel.: +55 21 2562 6538;
ax:  +55 21 2280 8193.
E-mail  address: mohana@biof.ufrj.br (R. Mohana-Borges).
166-0934/© 2011 Elsevier B.V.    
oi:10.1016/j.jviromet.2011.04.029
Open access under the Elsevier OA license.© 2011 Elsevier B.V. 
are available today, including the following: (i) virus isolation; (ii)
viral RNA direct detection; and (iii) virus-speciﬁc antibody determi-
nation. Antibody determination has the advantages of lower costs
and more widely available reagents, but it has the disadvantage
of poor early detection of infection (Kao et al., 2001). Alcon et al.
(2002) showed that the NS1 protein circulates in human serum
mostly from days 1–6 after the onset of clinical symptoms, with
the peak NS1 antigen detection occurring between days 3 and 5
in both primary and secondary infections. These properties make
it an attractive marker for developing a diagnostic detection test
for the beginning of symptoms. Currently, there are at least two
commercially available kits for DENV NS1 detection: the PlateliaTM
dengue NS1 kit (Bio-Rad Laboratories, Marmes La Coquette, France)
and the Pan-E dengue early ELISA kit (Panbio Diagnostics, Brisbane,
Australia).
In the present study, the NS1 protein was  expressed in E. coli
bacterial cells and four different refolding protocols were tested
to verify the refolding efﬁciency for producing polyclonal antibod-
ies against NS1. The investigation of the oligomeric state of NS1
showed dimer formation in almost all of the methods used, consis-
Open access under the Elsevier OA license.tent with the oligomeric state observed in the native-mammalian
NS1 protein. Moreover, the polyclonal antibodies generated from
the E. coli recombinant NS1 (rNS1) protein were shown to recognize
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The ﬂuorescence spectroscopy measurements were performed
in a Varian Cary Eclipse spectroﬂuorometer (Australia). The excita-
tion wavelength was ﬁxed at 278 nm,  and the emission spectrum
was recorded from 300 to 420 nm.  All the experiments were per-
Table 1
Buffer used for cell resuspension, inclusion bodies puriﬁcation and protein refolding.
Buffer Composition
Buffer A 50 mM Tris–HCl pH 8, 100 mM NaCl and 1 mM
-mercaptoethanol
Buffer B 50 mM Tris–HCl pH 8, 100 mM NaCl, 1 mM
-mercaptoethanol and 8 M urea
Buffer BI 50 mM Tris–HCl pH 8, 100 mM NaCl, 1 mM
-mercaptoethanol, 8 M urea and 0.5 M imidazole
Buffer ASB 50 mM Tris–HCl pH 8, 100 mM NaCl, 1 mM
-mercaptoethanol and 0.1% (w/v) ASB-14
Buffer TA 50 mM Tris–HCl pH 8, 0.4 M l-arginine, 1.0 mM GSH
(glutathione, reduced) and 0.1 mM GSSG (glutathione,10 D. Allonso et al. / Journal of Viro
ositive serum from DENV2-infected patients. In addition, a panel
f 43 sera was tested by a capture ELISA assay, resulting in a 100%
etection of DENV2-positive serum and a 60% detection of DENV
gM-positive serum, which was not detected either by the PanBio
r Platelia diagnostic kits. These results conﬁrmed the utility of the
olyclonal antibodies raised from rNS1 for developing a sensitive
nd low-cost serological test for rapid and early diagnosis of DENV
nfection, making it ideal for larger population screening.
. Material and methods
.1. Ethics statement
The rabbit and mouse antibody production was conducted in
ompliance with the ethical standards for animal experimenta-
ion of the Brazilian College of Animal Experimentation and was
pproved by the Institute’s Animal Use Ethical Committee (CEUA-
IOCRUZ) (number L-067/08). The human samples were collected
s part of an ongoing project in the Flavivirus Laboratory and the
roject was approved by the Ethics Committee on Human Research
CEP: 274/05).
.2. Construction of the pETNS1his plasmid
The DENV2 ns1 gene was ampliﬁed by PCR and cloned in
he pET23b plasmid (Novagen, USA). The total RNA from C6/36
ells infected with DENV2 New Guinea C strain (NGC) was
xtracted with Trizol (Invitrogen, USA) according to the manufac-
urer’s protocol and was used as a template for cDNA synthesis.
he cDNA synthesis was performed with the antisense primer
′-CATAAGCTTACAGAGGTTCCCCCATG-3′, which hybridizes with
he nucleotide sequence 1422–1438 within the ns3 gene. The
DNA was then used to amplify the ns1 gene sequence, with
ense 5′-GGGGGATATCGATAGTGGTTGCGTTG-3′ and antisense 5′-
GGGCTCGAGGGCTGTGACCAAG-3′ primers containing restriction
ites for EcoRV and XhoI, respectively. The PCR was performed as
ollows: 2 min  at 94 ◦C followed by 30 cycles of 1 min  at 92 ◦C, 1 min
t 55 ◦C, and 2 min  at 72 ◦C, with an extension step of 5 min  at 72 ◦C.
he ampliﬁed product was electrophoresed on a 1% agarose gel,
ecovered with glass beads, puriﬁed using a GeneClean kit (Strata-
ene, USA), digested with EcoRV and XhoI, and ligated to a pET23b
ector that was  previously digested with these same enzymes.
hemically competent E. coli DH5 cells were transformed with the
igation products, and the recombinants were screened by restric-
ion mapping and sequencing using an ABI PRISM dye terminator
ycle sequencing core kit (Applied Biosystems, USA). The recombi-
ant plasmid, named pETNS1his, was isolated by alkaline lysis and
uriﬁed using a Qiagen Plasmid Mini Kit (Qiagen, Germany).
.3. Expression of the NS1 protein and puriﬁcation from inclusion
odies
Chemically competent E. coli cells BL21(DE3)pLyS were trans-
ormed with 200 ng of the pETNS1his plasmid, and positive clones
ere selected in an LB-agar medium containing 100 g/mL ampi-
illin and 34 g/mL chloramphenicol at 37 ◦C overnight. A single
ositive colony was pre-inoculated in 10 mL  of LB medium contain-
ng 100 g/mL ampicillin and 34 g/mL chloramphenicol, and this
ulture was stirred at 200 rpm at 37 ◦C overnight. The overnight
ulture was diluted to 1:50 in 1 L of fresh antibiotic-containing
edium and grown at 37 ◦C until an optical density (O.D.600 nm)
f approximately 0.7–0.8 was reached. The induction of protein
xpression was conducted with 0.5 mM IPTG followed by 3 h of
xpression. Then, the cells were harvested by centrifugation at
000 × g for 20 min  at 4 ◦C, and the total-cell lysate was prepared.
he pellet was resuspended in 25 mL  of Buffer A (Table 1) withl Methods 175 (2011) 109– 116
1  mM PMSF. Then, 5 mg/mL  of lysozyme, 10 g/mL of DNase A, and
5 mM of magnesium chloride were added, and the solution was
incubated for 30 min  at 4 ◦C with stirring. The total-cell lysate was
sonicated using 10 cycles of 15 s on and 1 min  off at 40% amplitude.
The puriﬁcation of inclusion bodies was performed by centrifuga-
tion at 37,200 × g for 20 min  at 4 ◦C. Finally, the inclusion bodies
were resuspended in Buffer B (Table 1) overnight at 4 ◦C.
2.4. NS1 puriﬁcation by afﬁnity chromatography
Because recombinant NS1 (rNS1) has a 6× histidine tag at its C-
terminal end, a Ni2+NTA afﬁnity chromatography (HisTrap HP 5 mL;
GE Healthcare, USA) was  used to purify the protein from the inclu-
sion bodies. After equilibrating the column with 5 column volumes
(CV) of Buffer B, the protein was  loaded into the column with a ﬂow
of 1 mL/min, followed by a 10-CV wash with Buffer B to remove all
the nonspeciﬁc binding proteins. The elution was performed using
a gradient of Buffers B and BI (Table 1) at a ﬂowrate of 2 mL/min.
All the collected samples were analyzed by 12% SDS-PAGE, and the
tubes containing the rNS1 were pooled for further refolding.
2.5. rNS1 refolding
Four distinct methods were used to evaluate the refolding efﬁ-
ciency of rNS1. In each protocol, 5 mg  of urea-denatured rNS1 were
adjusted to 100 g/mL prior to the refolding step. In Protocol I, the
denatured rNS1 was subjected to a slow 20-fold dilution with Buffer
ASB (Table 1), followed by a ﬁnal dialysis in 50 mM Tris–HCl (pH
8), 100 mM NaCl, 1 mM DTT and 0.05% ASB-14. In Protocol II, the
protein was  subjected to a slow 20-fold dilution with Buffer ASB
followed by dialysis in PBS (8.06 mM sodium phosphate, 1.94 mM
potassium phosphate, 2.7 mM KCl, and 137 mM NaCl, pH 7.4). Pro-
tocol III consisted of dialysis of the protein in Buffer TA (Table 1)
for three days with two buffer changes, followed by a ﬁnal dialysis
in PBS as has been previously described (Das et al., 2009). In Pro-
tocol IV, denatured rNS1 was subjected to a slow 20-fold dilution
with Buffer TNA (Table 1) followed by ﬁnal dialysis in PBS. All these
experiments were performed at 4 ◦C. The refolded proteins were
named NS1I, NS1II, NS1III and NS1IV, corresponding to protocols
I, II, III and IV, respectively. After refolding, the proteins were con-
centrated using a Centriprep YM-10 system (Millipore Corporation,
USA) to a ﬁnal concentration of approximately 1.5 mg/mL.
2.6. Fluorescence spectroscopy and circular dichroismoxidized)
Buffer TNA 50 mM Tris–HCl pH 8, 100 mM NaCl, 0.4 M l-arginine,
1.0 mM GSH (glutathione, reduced) and 0.1 mM GSSG
(glutathione, oxidized)
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ormed at 25 ◦C. The circular dichroism (CD) experiments were
onducted in a Chirascan Circular Dichroism Spectropolarimeter
Applied Photophysics, UK) at 20 ◦C using a quartz cuvette with a
.01 cm path length. Spectra from three scans at a 30 nm/min speed
ere averaged, and the buffer baselines were subtracted from their
espective sample spectra. The secondary structure was  estimated
rom ﬁtting the far-UV CD spectra using the CDSSTR method, which
s available on the Dichroweb server (Whitmore and Wallace, 2004,
008).
.7. Anti-rNS1 antibody production
Five-week-old male Balb/c mice were intraperitoneally immu-
ized with 20 g of rNS1II per animal in complete Freund’s adjuvant
Sigma, USA) followed by four injections of the protein in incom-
lete Freund’s adjuvant (Sigma, USA), which were administered
wo weeks apart. Two weeks after the ﬁnal immunization, the
nimals were euthanized and bled by total cardiac puncture. A
hree-month-old isogenic male rabbit was ﬁrst immunized sub-
utaneously with 1 mg  of rNS1II in complete Freund’s adjuvant
ollowed by two subcutaneous injections of rNS1 in incomplete
reund’s adjuvant, which were administered two  weeks apart. One
eek after the ﬁnal immunization, approximately 20 mL  of blood
as obtained by ear bleeding. The serum samples were stored at
20 ◦C for subsequent analysis.
.8. Western blot analysis
The rNS1 proteins refolded by the four different protocols were
ubjected to heat treatment for 10 min  in the presence of 2 mM DTT
r non-heat treatment in the absence of reducing agents prior to
nalysis (Costa et al., 2006b). To remove albumin and to enhance
he detection of less-abundant proteins of the patient’s serum,
0 L of seven sera were treated with Cibacron blue resin (Sigma,
SA) and were further concentrated by adding 5× volumes of cold
cetone and incubated for 2 h at −20 ◦C, centrifuged at 13,400 × g
or 20 min  at 4 ◦C and then resuspended in half of the initial vol-
me. All the samples were separated by electrophoresis on 12%
DS-PAGE and transferred onto Hybond ECL nitrocellulose mem-
ranes (GE Healthcare, Sweden). The nitrocellulose membrane was
locked with 5% skim milk in TBST (0.1% Tween 20 in TBS [25 mM
ris–HCl pH 7.4, 3 mM KCl, and 140 mM NaCl], pH 7.6) for 2 h fol-
owed by overnight incubation with an anti-rNS1 polyclonal serum
iluted to 1:10,000 (for the reactions with the refolded NS1, whole
ell extracts and culture supernatant) or with puriﬁed anti-rNS1
olyclonal antibody diluted to 1:500 (for the reactions with the
atient’s serum). The membrane was then washed three times
ith TBST, incubated for 2 h with anti-mouse IgG conjugated to
orseradish peroxidase (Promega, USA) diluted to 1:2500 in block-
ng solution, washed again, developed with a Picotag kit (Pierce,
SA) and exposed to Kodak MXG/PLUS ﬁlm. The anti-NS1 antibody
as puriﬁed by incubating the rNS1-protein-containing nitrocel-
ulose membrane with anti-NS1 mouse serum for 48 h, eluting the
uriﬁed antibody with 0.2 M glycine and 1 mM EDTA at pH 4 and
eutralizing with 10 mM Tris base.
.9. Enzyme-linked immunosorbent assay (ELISA) for NS1
etection
The ELISA was performed with a recombinant NS1 glycoprotein
xpressed in insect cells (Hawaii Biotechnology Group), and the
our NS1 proteins were refolded using the protocols described pre-
iously. The proteins were used as the solid-phase bound antigen,
nd the epitope speciﬁcity was evaluated using a serum sample
ollected from mice immunized with a DNA vaccine that elicited
ntibodies recognizing native DENV2 NS1 protein (Costa et al.,l Methods 175 (2011) 109– 116 111
2006a). Wells of MaxiSorp plates (Nalge Nunc, Denmark) were
coated with 0.4 g of rNS1 protein expressed in E. coli or with
0.1 g of the insect-cell NS1, both in 100 L of PBS at 37 ◦C for
1 h. The plates were blocked overnight at 4 ◦C with 2% skim milk
in PBST (0.05% Tween 20 in PBS), washed with PBST and incu-
bated with serial dilutions of serum for 1 h at 37 ◦C. The plates were
then washed again and incubated with goat anti-mouse IgG conju-
gated with horseradish peroxidase (Southern Biotechnology, USA)
for 1 h at 37 ◦C. The reactions were visualized after 20 min  at room
temperature with ortho-phenylenediamine dihydrochloride (OPD)
(Sigma, USA) and H2O2 as a substrate and 9 N H2SO4 as the stop-
ping solution, followed by absorbance measurement at 490 nm.  The
titers were deﬁned as the reciprocal of serum dilution, which gave
an absorbance above that of the corresponding pre-immune serum.
2.10. Capture ELISA with patient’s serum
The wells of MaxiSorp plates were coated with 100 L of mice-
produced anti-NS1 polyclonal antibody diluted to 1:10 in PBS at
37 ◦C for 1 h and blocked overnight at 4 ◦C with 2% skim milk in
PBST. The wells were washed ﬁve times with PBST prior to incu-
bation for 30 min  at 37 ◦C with 10 L of the patient’s serum that
had been diluted in PBS to a ﬁnal volume of 50 L. Afterwards,
the wells were incubated with 100 L of rabbit-produced anti-
NS1 polyclonal antibody diluted to 1:20,000 in PBS for 1 h at the
same temperature, followed by incubation with anti-rabbit IgG
conjugated with horseradish peroxidase (Promega, USA) for 1 h
at 37 ◦C, and it was then washed again with PBST. The reactions
were visualized after 20 min  at room temperature with OPD, H2O2
as the substrate and 9 N H2SO4 as the stopping solution followed
by absorbance measurement at 490 nm.  Negative controls were
performed in the absence of the NS1 antigen, and the absorbance
values were corrected using the mean value of the negative con-
trols.
3. Results
3.1. Expression and puriﬁcation of rNS1 from E. coli
The DENV2 ns1 gene was cloned into the pET23b plasmid in the
correct open reading frame. The transformed BL21(DE3)pLyS bac-
terial cells expressed a high level of the recombinant NS1 protein as
inclusion bodies. After solubilization with urea, the rNS1 was  suc-
cessfully puriﬁed using a HisTrap Ni2+NTA afﬁnity column, with a
ﬁnal protein yield of approximately 130 mg/L bacterial culture.
3.2. rNS1 refolding
Four different protocols were used to evaluate the best refolding
strategy for rNS1. Protocol I used slow dilution of the urea-
denatured rNS1 in ASB buffer composed of a zwitterionic detergent
that stabilizes protein interactions at the critical point of refolding.
About 90% of the rNS1 protein was  recovered using this method
(Table 2). In Protocol II, the rNS1 was  also subjected to slow dilu-
tion with an ASB buffer, but the ﬁnal dialysis was  performed in
PBS instead of a refolding buffer, resulting in an 82% protein refold-
ing yield (Table 2). Both of these protocols were successfully used
to obtain properly refolded rNS1 at high protein concentrations
(above 1 mg/mL) (data not shown). Protocol III used dialysis in a TA
buffer but was limited to a protein concentration below 100 g/mL
due to protein aggregation (Das et al., 2009). This protocol yielded
a protein recovery of about 67% (Table 2). Protocol IV consisted
of slow dilution of the urea-denatured rNS1 in TNA buffer; 82% of
the refolded protein was obtained after the ﬁnal dialysis in PBS
(Table 2). The signiﬁcant differences between Protocols III and IV
include the presence of NaCl, which stabilizes the refolded protein,
112 D. Allonso et al. / Journal of Virological Methods 175 (2011) 109– 116
Table  2
Protein recovery of the refolding protocols.
Protocol rNS1 Refolding buffer Refolding method Initial mass (mg) Final mass (mg) Protein recovery (%)
I NS1I Buffer ASB Dilution 5 4.4 90
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rNS1 protein (Fig. 2C). The glycosylated NS1 protein produced in
the insect cells was  used as a positive control. Taken together,
these results suggest that the NS1 obtained from the E. coli
adopted a conformation similar to that of the NS1 obtained in
Fig. 1. Analysis of tertiary and secondary structures of refolded proteins. (A) All
refolded proteins were analyzed using ﬂuorescence spectroscopy in order to verifyII NS1II Buffer ASB with ﬁnal dialysis in PBS Dilution
III NS1III Buffer TA with ﬁnal dialysis in PBS Dialysis
IV  NS1IV Buffer TNA with ﬁnal dialysis in PBS Dilution
nd the choice of dilution for protocol IV, which allowed the use of
arger amounts of protein without aggregation. Notably, the rNS1
rom Protocol II was chosen to produce the anti-NS1 antibodies
ecause this protocol is the most cost-effective and generated the
ighest protein-recovery yield.
.3. Spectroscopic analysis of refolded rNS1
The four refolding protocols used for the urea-denatured rNS1
ere analyzed by ﬂuorescence spectroscopy of the Tryptophan
Trp) residue to verify whether the protein obtained in each
rotocol was properly folded. Trp is an excellent intrinsic ﬂuo-
escence probe because its ﬂuorescence spectrum shifts to higher
avelengths as it becomes more exposed to solvent (Melo et al.,
009). The DENV2 NS1 protein contains 14 tryptophan residues;
s expected, a peak at approximately 340 nm was observed in the
mission spectra of the refolded rNS1 obtained from all of the
efolding protocols, and a peak at 355 nm was observed in the dena-
ured rNS1 emission spectrum (Fig. 1A). These results conﬁrm that
he four protocols used in the present work were able to refold the
NS1 protein correctly because a peak of 340 nm is usually observed
n proteins with an intact tertiary structure, whereas unfolded pro-
eins present a maximum single peak at approximately 350 nm.
The refolded rNS1 proteins were also analyzed by CD to inves-
igate their secondary structure. An analysis of their far-UV CD
pectra showed two negative peaks, one at 208 nm and another
ubtle peak of lower intensity at 225 nm,  indicating a mixture
f secondary-structure components (Fig. 1B). According to the
DSSTR decomposition algorithm, the rNS1 protein obtained from
ll the refolding protocols was composed of 27% -helices, 43%
-sheets and 30% random coils/turns.
.4. Investigation of rNS1 oligomeric state
Prior to their analysis in SDS-PAGE and western blot, the
efolded rNS1 proteins were subjected to either heat treatment
n the presence of reducing agent or non-heat treatment in the
bsence of reducing agent to verify their oligomeric state. A band
f 45 kDa corresponding to the rNS1 protein was visualized in all
f the heated samples (Fig. 2A). Another band of approximately
8 kDa was also observed in those lanes, which may  have corre-
ponded to an NS1 degradation product (Fig. 2A). These bands were
lso conﬁrmed to be DENV2 NS1 by mass spectrometry (data not
hown). In addition, bands at 40 kDa, 80 kDa and above 200 kDa
ere clearly observed in the unheated NS1II, NS1III and NS1IV sam-
les; these three bands corresponded to the monomers, dimers
nd (probably) hexamers of rNS1, respectively (Fig. 2A). A differ-
nce in apparent molecular weight between the monomers of the
eated and unheated samples was probably observed because the
eated NS1 was not as compact as the unheated protein, resulting
n altered migration through SDS-PAGE. A western blot analysis of
hese samples conﬁrmed the SDS-PAGE bands (Fig. 2B). Interest-
ngly, while no 80 kDa band was observed in the unheated NS1I
ample in SDS-PAGE (Fig. 2A), the western blot showed a low-
ntensity band in that position (Fig. 2B). This ﬁnding conﬁrmed the
resence of dimeric rNS1 under this refolding condition, although
 lower quantity was observed than in other refolding protocols.5 4.0 82
5 3.3 67
5 4.0 82
To determine whether the rNS1 proteins assumed the correct
native structure, an ELISA assay was  performed using a poly-
clonal antibody that recognized the conformational epitopes of
the NS1 protein produced in the NS1-DNA vaccinated mice (Costa
et al., 2006b).  The results indicated that all of the proteins were
recognized by conformational-speciﬁc antibodies (Fig. 2C). Nev-
ertheless, the antibody titers varied signiﬁcantly depending on
the refolding protocol, with values of 4500, 22,000, 28,000 and
130,000 for NS1I, NS1II, NS1IV and NS1III, respectively (Fig. 2C).
These titration results correlate well with the amount of dimeric
rNS1 detected by the western blot analysis (Fig. 2B), in which
the highest titer (130,000) was  achieved by NS1III, the refold-
ing condition that also produced the greatest amount of dimerictertiary structure content. The excitation wavelength was ﬁxed at 278 nm and the
emission spectrum was  recorded from 300 nm to 420 nm. (B) Circular dichroism
spectra of all refolded NS1 proteins. Experiments were performed at 20 ◦C. Spectra
were averaged from three scans at a 30 nm/min speed, and the buffer baselines were
subtracted from their respective sample spectra.
D. Allonso et al. / Journal of Virological Methods 175 (2011) 109– 116 113
Fig. 2. Analysis of the oligomeric state of rNS1. The four refolded rNS1 samples
were subjected to a heated and non-heated treatment in the presence or absence of
2  mM DTT, respectively, followed by analysis in 12% SDS-PAGE (A) and western blot
using an anti-NS1 polyclonal antibody (B). H, heating treatment; NH, non-heating
treatment. (C) Evaluation of the tertiary structure integrity of rNS1. Four different
refolded rNS1 samples were tested by ELISA using a polyclonal antibody that rec-
ognizes conformational epitopes against native NS1 glycoprotein produced in mice
immunized with a DNA vaccine based on the NS1 gene. Puriﬁed recombinant NS1
glycoprotein expressed in insect cells was used as a positive control. Titers were
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Fig. 3. Detection of the NS1 antigen in serum samples of dengue patients by west-stablished as the reciprocal serum dilutions that gave an absorbance above that of
reimmune sera. Data represent the mean of duplicate values for each sample and
ars  show the standard deviation of the mean. PC, positive control.
he native, glycosylated form and it maintained its immunogenic
roperties.
.5. Analysis of the serum samples of dengue-infected patients
The mouse hyperimmune serum raised against the bacterial
NS1 was able to detect both the linear and conformational epi-
opes of the NS1 glycoprotein produced during viral infection
Suppl. Figs. S1 and S2).  Based on these results, four serum samples
ere collected from acute-phase (5–7 days after symptom onset)
ENV2-infected patients, and three negative control samples wereern blot using mouse puriﬁed anti-NS1 polyclonal antibody. Lanes 1–3, negative
sera; 4–7, different serum samples from acute-phase DENV2-infected patients. All
samples were ﬁrst subjected to albumin depletion using Cibacron Blue resin.
analyzed by western blot assay using puriﬁed anti-rNS1 poly-
clonal antibody. The results showed a single band of approximately
50 kDa, corresponding to the glycosylated NS1 in its monomeric
form, in all the infected patients’ sera. However, no such band was
observed in the negative controls’ (healthy patients’) sera (Fig. 3).
These observations conﬁrm that the polyclonal antibody produced
from the rNS1 protein recognized the NS1 antigen secreted in the
dengue-infected patients. These results also indicate that this anti-
body can be an important tool for detecting dengue infection from
patient’s sera.
3.6. The capture ELISA for NS1 detection in different patient’s
serum samples
To assess the usefulness of the polyclonal antibodies generated
by the rNS1 expressed in E. coli for the early detection of dengue
infection, a capture ELISA was  performed using puriﬁed anti-rNS1
mouse polyclonal antibodies to capture the NS1 antigen and an
anti-rNS1 rabbit polyclonal antibody as the secondary detector.
The cutoff value was  calculated as twice the value of the negative
control. A panel of 43 serum samples collected from the patients
on different days of the infection’s course (with day 0 deﬁned
as the ﬁrst day of fever) was  analyzed. The panel included sam-
ples from acute-phase patients infected with DENV1, DENV2, and
DENV3 and from DENV-infected patients in the beginning of the
clearance phase. The dengue infection in these patients was  not
detected by any of the commercial NS1-based diagnostic kits, such
as the PlateliaTM dengue NS1 and Pan-E dengue early ELISA kits
(Table 3). Three negative samples from patients not infected with
DENV were also analyzed to validate the experiment. As expected,
the O.D.490 nm values measured from the non-infected patients’ sera
were below the cutoff line, while all of the DENV2 sera’s values were
above this line (Fig. 4 and Table 3 – S1 to S13), including the sam-
ple that was not detected by the PanBio kit (Fig. 4 and Table 3 –
S5), resulting in an 100% sensitivity for the DENV2 samples. The
differences observed in the O.D.490 nm values were related to the
differences in the amount of plasma-circulating NS1, which varied
from 1 to 10 g/mL depending on the patient’s susceptibility, the
virus virulence (Alcon et al., 2002) and the levels of free antigen
after the eventual formation of immune-complexes with anti-NS1
IgM/IgG.
Interestingly, this method successfully detected the DENV1 NS1
in 6 of the 10 samples (Fig. 4 and Table 3 – S14, S16, S17, S18, S20 and
S21). Surprisingly, 60% (6/10) of the DENV-positive samples col-
lected from patients at the beginning of the clearance phase, which
were not detected by any of the commercial kits, were detected by
the method used here (Fig. 4 and Table 3 – S34, S35, S40, S41, S42
and S43). This result suggests that the polyclonal antibodies pro-
duced against the correctly refolded NS1 expressed by the bacteria
could recognize the circulating serum NS1 protein at low levels and
when immune complexes were already present. However, no NS1
was detected in the DENV3-infected patients’ sera (Fig. 4). Alto-
gether, these results suggest the potential utility of this method for
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Table  3
NS1 detection of the patients’ sera by Capture ELISA.
Sample Days post-infection IgM 1 IgG 1 Virus type NS1 PanBio NS1 Platelia This work
N1 N.D. N.D. N.D. Neg Neg Neg Neg
N2 N.D. N.D. N.D. Neg Neg Neg Neg
N3 N.D. N.D. N.D. Neg Neg Neg Neg
S1  03 N.D. N.D. DENV2 Pos Pos Pos
S2 04  N.D. N.D. DENV2 Pos Pos Pos
S3  01 N.D. N.D. DENV2 Pos Pos Pos
S4  03 N.D. N.D. DENV2 Pos Pos Pos
S5  06 Pos Pos DENV2 Neg Pos Pos
S6 09 Pos Pos DENV2 Pos Pos Pos
S7  09 Pos Pos DENV2 Pos Pos Pos
S8 09  Pos Pos DENV2 Pos Pos Pos
S9  N.D. N.D. N.D. DENV2 N.D. N.D. Pos
S10  N.D. N.D. N.D. DENV2 N.D. N.D. Pos
S11  N.D. N.D. N.D. DENV2 N.D. N.D. Pos
S12 N.D. N.D. N.D. DENV2 N.D. N.D. Pos
S13 N.D. N.D. N.D. DENV2 N.D. N.D. Pos
S14  03 Neg N.D. DENV1 Pos Pos Pos
S15 04 Neg Pos DENV1 Pos Pos Neg
S16  03 Neg N.D. DENV1 Pos Pos Pos
S17 03 Neg N.D. DENV1 Pos Pos Pos
S18  0 Pos N.D. DENV1 Neg Pos Pos
S19  0 Neg N.D. DENV1 Neg Pos Neg
S20  03 Neg N.D. DENV1 Pos Pos Pos
S21  02 Neg Pos DENV1 Pos Pos Pos
S22 04 Neg N.D. DENV1 Pos Pos Neg
S23  05 Neg N.D. DENV1 Pos Pos Neg
S24 01 N.D. N.D. DENV3 Pos Pos Neg
S25  0 Neg N.D. DENV3 Pos Pos Neg
S26  08 Neg N.D. DENV3 Neg Pos Neg
S27 03 N.D. N.D. DENV3 Pos Pos Neg
S28  03 N.D. N.D. DENV3 Pos Pos Neg
S29 05 Neg N.D. DENV3 Pos Pos Neg
S30  02 N.D. N.D. DENV3 Pos Pos Neg
S31 02 N.D. N.D. DENV3 Neg Pos Neg
S32  0 N.D. N.D. DENV3 Pos Pos Neg
S33  02 N.D. N.D. DENV3 Pos Pos Neg
S34 04 Pos N.D. N.D.a Neg Neg Pos
S35  04 Pos N.D. N.D.a Neg Neg Pos
S36 05 Pos N.D. N.D.a Neg Neg Neg
S37  07 Pos N.D. N.D.a Neg Neg Neg
S38  06 Pos N.D. N.D.a Neg Neg Neg
S39  07 Pos N.D. N.D.a Neg Neg Neg
S40  04 Pos N.D. N.D.a Neg Neg Pos
S41 06 Pos N.D. N.D.a Neg Neg Pos
S42  03 Pos N.D. N.D.a Neg Neg Pos
S43 06 Pos N.D. N.D.a Neg Neg Pos
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c.D., not determined.
a Virus detected but not determined.
eveloping a sensitive, low-cost, and early detection test for DENV
nfection.
. Discussion
Different heterologous protein expression systems, such as
east expression systems, vaccinia virus, baculovirus and other
nsect cells, have been proposed for producing recombinant DENV
S1 protein (Falgout et al., 1989; Falgout and Markoff, 1995; Pryor
nd Wright, 1993, 1994; Wallis et al., 2004; Wu et al., 2003; Zhao
t al., 1987; Zhou et al., 2006), and these methods are suitable
rotocols for generating glycosylated protein. Because these are
omplex systems, however, manipulation and protocol optimiza-
ion are expensive and time consuming. By contrast, prokaryotic
ystems are easy to manipulate, allow rapid protocol optimization
nd express high levels of recombinant proteins but lack post-
ranslational modiﬁcations. Several reports have also proposed
chieving NS1 expression using bacterial cells (Das et al., 2009;
ason et al., 1990; Qiu et al., 2009; Xu et al., 2006), but none of
hese studies were able to produce a high yield of functional and
orrectly folded NS1 protein.Four different refolding strategies were evaluated to determine
which one generated the best refolding efﬁciency and restored
the structural properties of the NS1 protein expressed by E. coli
BL21(DE3)pLyS cells. All the protocols were able to recover
the rNS1 efﬁciently, and their integrity was conﬁrmed by ﬂuo-
rescence and CD spectroscopy. Another protocol for recovering
rNS1 protein has been published recently, but it had an efﬁ-
ciency yield of 2.6% (Amorim et al., 2010). Unfortunately, it was
not possible to reproduce this ﬁnding because all of the proteins
aggregated immediately under the buffer conditions used in the
study.
The NS1 protein exists predominantly as a heat-sensitive
homodimer, which may  be its functional form (Winkler et al., 1988,
1989). The expression by COS cells of mutant NS1 that lacks glycan
chains reveals that this protein is able to form dimers, although
they are less stable than dimers of the glycosylated protein (Pryor
and Wright, 1994). It has been previously reported that dimers
of rNS1 failed to form when the protein was  expressed in E. coli
(Lemes et al., 2005). The rNS1 obtained from all of the four refolding
protocols was able to form dimers, although in differing amounts.
These results clearly indicate that E. coli rNS1 is able to form
D. Allonso et al. / Journal of Virologica
Fig. 4. Capture ELISA using puriﬁed mouse anti-NS1 polyclonal antibody to cap-
ture the NS1 antigen from serum samples of dengue patients and rabbit anti-NS1
antiserum as the secondary detector. The cut-off value was  calculated as twice the
mean value of the negative control (O.D.490 nm = 0.203). Neg, negative serum sam-
ples;  DENV2, serum samples collected from DENV2-infected patients during the
acute phase; DENV1, serum samples collected from DENV1-infected patients dur-
ing the acute phase; DENV3, serum samples collected from DENV3-infected patients
during the acute phase; N.D., serum samples from DENV IgM-positive patients at the
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Appendix A. Supplementary dataeginning of the clearance-phase but not determined by either PanBio or Platelia
engue diagnosis kits.
imers, depending on the protocol used to recover it. It is worth
entioning that the rNS1 generated by all of the methods was
n the correct conformation. Because all the samples were recog-
ized by a conformational-speciﬁc antibody and recognition was
ependent on the amount of dimeric rNS1 formed, this result rein-
orces the proposal that the oligomeric (dimer) state is important
or NS1 immunogenicity. The analysis of the anti-NS1 polyclonal
ntibodies raised against the rNS1II indicates that they are able
o recognize not only conformational but also linear epitopes that
re maintained in both folded and unfolded proteins, which high-
ights their utility as tools for dengue laboratory research and
iagnosis.
Because rapid and accurate diagnosis of dengue is critical for
ppropriate treatment, different approaches have been developed
o generate a sensitive acute-phase diagnostic assay (dos Santos
t al., 2004, 2007). It is known that the NS1 protein is secreted
nto the patient’s plasma at the beginning of clinical symptoms,
ostly from days 1 to 6 after the onset of fever (Alcon et al., 2002),
hich makes NS1 an important marker for detecting DENV infec-
ion in the ﬁrst few days after symptoms appear. In this scenario,
he anti-NS1 antibody is an attractive tool for the early diagno-
is of DENV-infected patients. Although there are commercially
vailable diagnostic kits that detect the NS1 antigen, develop-
ng new approaches is still relevant to improving sensitivity and
peciﬁcity. This study examined whether an anti-NS1 polyclonal
ntibody raised from a correctly refolded protein expressed by
. coli is able to recognize the NS1 found in human serum. A west-
rn blot analysis conﬁrmed that the puriﬁed anti-rNS1 polyclonal
ntibody was only able to recognize a single and speciﬁc band cor-
esponding to the NS1 protein in infected patients. Using a serum
olume ﬁve-fold smaller than that used in the commercial kits,
he approach proposed here was able to identify the NS1 anti-
en in all the sera from the DENV2-infected patients (i.e., there
as 100% sensitivity for DENV2). In addition, the NS1 antigen
as identiﬁed in 60% of the DENV-positive sera from the begin-
ing of the clearance-phase, which the commercial NS1-based
iagnostic kits were not able to do. This result highlights the sensi-
ivity of polyclonal antibodies for developing alternative diagnostic
pproaches to dengue detection. Interestingly, the method also
uccessfully detected 60% of the DENV1-infected samples. By con-l Methods 175 (2011) 109– 116 115
trast, no DENV3-infected serum was  detected. This result was  not
entirely unexpected because a band corresponding to the NS1 pro-
tein from some of the DENV3-infected sera was detected with much
lower intensity than that of the DENV-2 infected sera in the western
blotting assay (data not shown). Therefore, it seems that antibodies
to DENV2 NS1 cross-react with DENV3, albeit at a low level, as has
been reported previously (Falconar, 1997). In fact, the sensitivities
of the PlateliaTM dengue NS1 and Pan-E dengue early ELISA kits
vary with the DENV serotype (Ramirez et al., 2009), and both kits
poorly detected DENV3-infected samples (Lima et al., 2010). When
considering all the samples together (excluding the S9 to S13 sam-
ples, which were not analyzed by the abovementioned kits), the
method described here was able to detect 52.8% (20/38) compared
to 60.5% (23/38) for the PanBio and 73.3% (28/38) for the Platelia
kits. Although the proposed method seems to be less sensitive, both
of the commercial kits are based on monoclonal antibodies that
recognize a conserved epitope present in all four DENV serotypes,
whereas the method suggested above is based on a polyclonal anti-
body raised against DENV2 rNS1 protein that recognizes multiple
epitopes of the protein. Notably, although the polyclonal antibody
production is prone to batch-to-batch variability, this problem
can be overcome by immunoafﬁnity puriﬁcation and/or by estab-
lishing a standard titer for different antibody pools. These results
highlight the high sensitivity of the polyclonal antibodies raised
against the correctly folded rNS1 protein for detecting circulating
NS1 in serum. Moreover, the production of such antibodies, using
a low-cost, high-yield efﬁciency rNS1 refolding protocol, makes it
signiﬁcant for developing a sensitive and cost-effective early detec-
tion kit, which is important for countries suffering from dengue
outbreaks.
In conclusion, this work describes four efﬁcient refolding proto-
cols for producing rNS1 from E. coli that are able to form dimers in
a native-like protein conformation. Based on these data, Protocol II
combined a high yield of the recovered protein with preserved bio-
chemical and immunogenic properties and low-cost production,
making it the best method for refolding the rNS1 protein. This study
also demonstrated that the NS1 protein is composed of a mixture of
-helices, -sheets and random coils. Finally, a method for DENV
detection using the anti-NS1 polyclonal antibodies raised from cor-
rectly refolded rNS1 was  able to detect IgM-positive samples using
a ﬁve-fold lower sample quantity than the commercial PlateliaTM
dengue NS1 and Pan-E dengue early ELISA kits. Taken together,
these results demonstrate the utility of the correctly refolded rNS1
protein as a laboratory tool for dengue research and detection and
for developing a serological test for sensitive, rapid, early and reli-
able diagnosis of DENV infection.
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